Skip to main content
PMC home page
Frontiers in Physiology logoLink to Frontiers in Physiology
. 2020 Oct 16;11:562895. doi: 10.3389/fphys.2020.562895

A Randomized Controlled Trial on the Effects of 12 Weeks of Aerobic, Resistance, and Combined Exercises Training on the Serum Levels of Nesfatin-1, Irisin-1 and HOMA-IR

Sasan Amanat 1, Ehsan Sinaei 2, Mohammad Panji 3, Reza MohammadporHodki 4, Zahra Bagheri-Hosseinabadi 5, Hadis Asadimehr 6, Mohammad Fararouei 7, Aria Dianatinasab 8,*
PMCID: PMC7596362  PMID: 33178035

Abstract

Background/objective: This study aimed to investigate the impacts of a 12-week training of the aerobic exercise (AE), resistance exercise (RE), and combined exercise (CE) on the serum levels of nesfatin-1, irisin-1 and some other metabolic and anthropometric indices in overweight women with metabolic syndrome.

Methods: Sixty overweight women with metabolic syndrome were assigned equally into four groups: aerobic exercise (AE, n = 15), resistance exercise (RE, n = 15), combined exercise (CE, n = 15), and control (n = 15). All groups underwent 12 weeks of intervention. The study variables were measured before and 24 h after the intervention period.

Results: Twelve weeks of training resulted in an increase of irisin-1 in the AE and CE groups and nesfatin-1 in all the intervention groups. As expected, all the trained groups exhibited a positive alteration in anthropometric indices and lipid profile in comparison with the control group. Besides, compared with the control group, insulin resistance (based on the homeostatic model assessment) in AE (p = 0.022), RE (p = 0.032), and CE (p < 0.001) groups were reduced significantly. According to the observed changes in the measured indices, serum irisin-1 was significantly correlated with body weight, BMI, body fat percentage, fasting insulin, and HOMA-IR. However, with regard to nesfatin-1, only a negative correlation was observed with body fat percentage and LDL-cholesterol.

Conclusions: The 12-week systematic training program changed circulating irisin-1 and nesfatin-1. Also, change in the serum irisin-1 and nesfatin-1 were correlated with the change in glycemic and anthropometric indices in addition to LDL-cholesterol. Also, exercise training significantly reduced fasting insulin and HOMA-IR in all the intervention groups.

RCT Registration Code: IRCT20180806040721N2.

Keywords: metabolic syndrome, irisin, HOMA-IR, exercise program, insulin, aerobic, resistance, nesfatin-1

Introduction

It is generally accepted that exercise has important beneficial effects on metabolic disorders associated with impaired energy homeostasis (Algul et al., 2017). It is also known that a delicate balance exists in the ratio of energy expenditure to energy intake and that the molecular mechanism underlying this balance is complex (Hawley and Holloszy, 2009). Many critical processes, including those related to hormonal factors and the nervous system, play important roles in maintaining this balance (Algul et al., 2017). The importance of skeletal muscle and adipose tissue as secretory organs of many energy-regulating hormones is well-known (Luo and Liu, 2016). However, studies show that the level of these hormones changes after training sessions but the exact mechanisms by which exercise regulates energy homeostasis via energy-related hormones are still unclear.

The potential effects of exercise on altering the levels of hormones involved in energy regulation (particularly irisin-1 and nesfatin-1) is an interesting topic that has attracted the attention of many researchers (Oh et al., 2006; Norheim et al., 2014; Dianatinasab et al., 2020). Previous research identified nesfatin-1 as a new hypothalamic anorectic peptide, which is involved in metabolic regulation and food intake via a leptin-independent mechanism (Oh et al., 2006). However, studies on the effects of training on nesfatin-1 level provided contradicting findings, i.e., no change (Ghanbari-Niaki et al., 2010), decrease (Bajer et al., 2015), and increase (Ahmadizad et al., 2015), in the level of nesfatin-1. It was reported that the serum level of irisin-1 rises for a short period of time immediately after an exercise session (Fox et al., 2018). It has been reported that elevated irisin-1 levels in response to chronic exercise may reduce weight in obese individuals and insulin resistance in patients with diabetes (Bostrom et al., 2012; Kim et al., 2016; Whillier, 2020). In addition, serum irisin-1 has been found to have an inverse correlation with glucose intolerance (Choi et al., 2013). It is not clear whether training can increase the baseline serum irisin-1, as even the short-term increase in serum irisin-1 due to exercise may cause some beneficial metabolic changes (Wang et al., 2017, 2018). However, the mechanism of these changes seems to be complicated since it is revealed that the lipid tissue is responsible for the baseline level of irisin-1 in the blood among obese individuals (Huh et al., 2012). Furthermore, the serum irisin-1 level is positively correlated with higher waist circumference, body fat mass, and unfavorable lipid profile (Crujeiras et al., 2014; Polyzos et al., 2018). Irisin-1 is an exercise-related hormone that increases the rate of energy consumption and reflects the individual's metabolic status. Irisin-1 is an important agent for evaluating the effect of treatment of diseases associated with metabolic impairment including obesity and diabetes (Algul et al., 2017).

With regard to the above facts, it is important to clarify the effects of training on hormones such as nesfatin-1 and irisin-1 that are involved in the regulation of energy homeostasis (Bajer et al., 2015; Algul et al., 2017). A training program may be used as a non-pharmacological treatment to raise the levels of these hormones and improve the energy balance. It is suggested that exercise-induced increase in the levels of irisin-1 and nesfatin-1 may reduce food intake and increase energy expenditure (Dianatinasab et al., 2020).

Putting aside the conflicting results, regular physical activity is prescribed for patients with different metabolic diseases including diabetes, dyslipidemia, and metabolic syndrome (Amanat et al., 2020). Metabolic syndrome, as a cluster of health-related conditions including glucose intolerance, hypertension, dyslipidemia, and central obesity is an overwhelming health problem across the globe (Kaur, 2014). Regardless of the molecular pathways, regular exercise, especially a program with a combination of aerobic and resistance training can improve most conditions related to metabolic syndrome (AminiLari et al., 2017).

To the best of our knowledge, the effects of a various training program on serum nesfatin-1 and irisin-1 using a well-designed controlled clinical trial have not been studied yet. This study aimed to evaluate the effects of AE, RE, and CE on two different energy regulatory hormones, i.e., nesfatin-1 and irisin-1. Therefore, this study meant to examine two hypotheses: (i) whether different training regimens including aerobic, resistance, and a combination of aerobic and resistance, alter the serum level of irisin-1, nesfatin-1 and HOMA-IR, and (ii) whether changes in the serum irisin-1, nesfatin-1 levels, and HOMA-IR are associated with changes in other metabolic and anthropometric parameters in women with metabolic syndrome.

Materials and Methods

Participants

The study was carried out in accordance with the declaration of Helsinki, and it was approved by the local ethics committee of Shiraz University of Medical Sciences (approval code: IR-SUMS-REC: 97-01-04-17589). Details of the study participants and the study protocol are available elsewhere (Dianatinasab et al., 2020).

We followed the CONSORT 2010 flow diagram (Figure 1) to conduct this randomized controlled trial in order to examine the effects of aerobic exercise (AE), resistant exercise (RE), and combined exercise (CE) on the levels of serum irisin-1, nesfatin-1, fasting plasma glucose (FPG), insulin, insulin resistance (HOMA-IR), lipid profile, and body composition in obese women with metabolic syndrome. Metabolic syndrome was confirmed when at least three of the following conditions were met: abdominal obesity (waist circumference >88 cm in women), triglyceride ≥150 mg/dL, HDL-cholesterol ≤ 50 mg/dL in women, hypertension (systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg), and increased FPG (≥100 mg/dL) (Expert Panel on Detection, 2001). Inclusion criteria for subjects were as follows: having at least three diagnostic criteria of metabolic syndrome, aged between 46 and 60 years, being premonopause, sedentary lifestyle, non-smoker, no history of cancer, no history of cardiovascular and musculoskeletal disorders, no use of dietary or ergogenic supplements, and willingness to take part in the study. A sedentary lifestyle was defined as <600 MET min/week based on the short term of the International Physical Activity Questionnaire (IPAQ) (Moghaddam et al., 2012). Exclusion criteria were unwillingness to continue with the intervention (missing more than 20% of the training sessions), pregnancy, starting a specific dietary regimen and changing medication. All selected participants read and signed a written informed consent form (except for illiterate participants who gave a verbal informed consent).

Figure 1.

Figure 1

Open in a new tab

Study flow diagram.

Study Design

The study protocol was registered with the Iranian Registry of Clinical Trials (IRCT) under the registration code of IRCT20180806040721N2. The study was conducted from February to June 2018 on 60 overweight/obese women with metabolic syndrome selected from women visiting a public clinic affiliated with Shiraz University of Medical Sciences, Iran. Block randomization with a block size of four was used for assigning the subjects into four groups: (I) AE, (II) RE, (III) CE, and (IV) the control group. Each group consisted of 15 women who were not blind to group assignments due to the nature of the intervention. However, neither the laboratory staff nor the data collectors or the biostatistician were aware of group assignments. The eligible women were contacted by a nurse to participate in the study. The women were informed of the study method and objectives and were asked to sign the informed consent form before the initiation of the study. The participants were examined by a general practitioner before commencing the study to ensure that the interventions would not jeopardize their health condition.

Intervention: The Training Program

The control group was advised not to change their physical activity during the study. Also, their compliance with the interventions was monitored every other week via phone calls.

All the participants in the intervention groups engaged in group-based training sessions. In all the training groups each session was started with 10 min of stretching exercises and ended with 10 min of balance exercises.

The control group was advised not to change their physical activity during the study. Also, their compliance with the interventions was monitored every other week via phone calls.

Aerobic exercise (AE) consisted of running on the treadmill (Cosmuse/hp model Saturn,® Germany) three times per week on non-consecutive days. In the group-based training sessions, the exercise time was increased gradually from 30 to 60 min in each session after 2 weeks. Each 60-min session included the exact order of stretching exercises, treadmill walking (15–20 min), rest (5–10 min), stationary cycling (15–20 min), and balance exercises. The exercise intensity was based on the maximum heart rate (HRmax) which was estimated for each participant with the following formula: HRmax = 208 − 0.7 × age (Tanaka et al., 2001). The intensity of training was started at 60% HRmax and was gradually elevated to 75% HRmax during each session. The heart rate was monitored using the wristband heart rate monitor. The accuracy of the wristband heart rate monitor was approved by comparing the results with those collected via electrocardiography.

Resistance training (RE): The exercise techniques were instructed to the women and their performance was supervised by professional trainers in group-based training sessions. The exercise was performed for 2 sessions per week (each session 60 min) during the first 2 weeks and was increased to 3 sessions on non-consecutive days per week. Forty minutes of strength training consisted of 2 sets of 10 different exercises, including bench press, seated row, shoulder press, chest press, lateral pull-down, abdominal crunches, leg press, leg extension, triceps pushdown, and seated bicep curls, for upper and lower parts of the body. All the resistance exercises were performed according to the National Strength and Conditioning Association guideline (Haff and Triplett, 2015).

The subjects had 8–10 repetitions for each exercise and 5–10 min of rest between each set. For the first 2 weeks of training, the intensity of the exercises was 60% one-repetition maximum (1RM) and was elevated to 75–80% 1RM from the 3rd week on. In order to estimate 1RM, participants were tested on the leg press and seated bicep curl for the upper and lower body at 2 non-consecutive days. After warm-up for leg press participants positioned in such that 90° knee flexion was created. A conservative weight was applied to the apparatus and participants were instructed to fully extend their knees and repeat the procedure until exhaustion. For seated bicep curl participants lifted the weight in the range of 100° to a full extension until exhaustion. Considering inexperience participants and the risk of injury, instead of direct measurement, the estimation of 1RM was performed for each participants using the Brzycki formula (Brzycki, 1993): 1RM = (Amount of displaced weight (kg)/((1.0278-(0.0278 × counts of repetitions))).

Combined exercise (CE): This group also participated in group-based training sessions, so that they performed both AE and RE simultaneously in one session. The CE group performed exercise two sessions a week for the first 2 weeks and three sessions for the rest of the intervention period. Each session was consisting of 20 min of walking on a treadmill, followed by 5 min rest and one set of strength training, consisting of 10 different exercises similar to the RE exercise program. The intensities of the aerobic and strength exercises were gradually increased according to the AE and RE protocols, respectively. Figure 2 demonstrates an overview of the study protocol.

Figure 2.

Figure 2

Open in a new tab

An overview of the study protocol.

Nutrition and Supplements

Before and after the intervention we evaluated dietary intake to collect data on dietary energy and macronutrient content using 24-h dietary recall. Data were entered into Nutritionist IV software (First Databank® Inc., Hearst Corp., San Bruno, CA) for analysis. Dietary intakes were presented as the amount of energy and macronutrients (protein, carbohydrate, fat, and fiber) per day for each participant. Eventually, these data were transferred to SPSS software for further analysis. The participants were also asked not to change their dietary habits during the study period. The participants were contacted every other week by a nutritionist to ensure that no major dietary changes occurred.

Measurement

Before the study intervention, we collected demographic data and several anthropometric indexes including body weight, height, waist, and hip circumference. To calculate body mass index (BMI) and waist-to-hip ratio (WHR), we measured anthropometric measures in two mornings (before and after intervention) while the participants were wearing no shoes and minimal cloths according to the WHO guideline (World Health Organization, 1995). Body composition, including body fat percentage (%BF) and skeletal muscle mass (SMM) were measured using the bioelectric impedance analysis (InBody 720; BioSpace®, Co., Korea) with light clothing, in the standing position and no vigorous exercise session for at least 6 h before the measurement. To increase the precision of the assessment, participants were instructed to maintain normal hydration status. Blood pressure was measured in a seated position after 5 min rest and the average of the two consecutive measurements was recorded.

Before the intervention, 5 mL of venous blood was taken from each participant in the morning after 12 h of fasting. The samples were incubated for 15 min in the room temperature for clotting and then centrifuged for 10 min in 4,000 rpm to separate serum. The serum was frozen at −70°C until the time of laboratory analysis. The blood samples were also collected 24 h after the last exercise session and all the above-mentioned processes on blood samples were repeated. Each sample was tested once for biochemical analysis unless the result was unusually out of normal range to confirmation.

Fasting plasma glucose (FPG), total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride were measured with commercial kits (Pars Azmoon®, Tehran, Iran) and an autoanalyzer (Biotecnica instrument®, Rome, Italy) using the photometric and enzymatic methods. The serum fasting insulin and serum irisin-1 and nesfatin-1 levels were assessed by the enzyme-linked immunosorbent assay (ELISA) method and using the human insulin kit (ZellBio®, Ulm, Germany) and human irisin-1 and nesfatin-1 kit (Phoenix Pharmaceuticals®, Burlingame, USA). HOMA-IR was calculated using the following formula: HOMA-IR= [fasting glucose (mg/dL) × fasting insulin (mU/L)/405].

Statistical Analysis

The sample size was calculated to detect the least-significant difference between the intervention groups in terms of the serum nesfatin-1 level after the intervention as large as 1.8 ng/ml (standard deviation: SD = 1.3). In addition, the alpha and power were set at 0.05 and 80%, respectively. Accordingly, the sample size was estimated as 15 participants per group (Huh et al., 2015; Shabani and Izaddoust, 2018). The Shapiro-wilk test was used to assess the normal distribution of data. The baseline measures of the individuals were compared using the one-way ANOVA test. Before and after intervention measures with normal and non-normal distributions were compared using Paired t-test and Mann-Whitney U-test, respectively. The effectiveness of exercise programs was examined by comparing the mean difference of changes in each variable using the ANCOVA test, adjusted for the baseline measures as a covariate, followed by the Bonferroni post-hoc test. We further checked the correlations between irisin-1 and nesfatin-1 with the study variables including. The significance level was set as p < 0.05, and the data analysis was performed using the IBM SPSS Statistics 25 (Armonk, NY: IBM Corp).

Results

Participants' Characteristics

Figure 1 presents the flow diagram of the current study. Among sixty women who met the inclusion criteria and accepted to participate, 57 completed the 12-week study period. The mean age (±SD) of participants was 54.5 (±6.9 years). Two (3.5%) of the participants were illiterate, 45 (79%) had a high school degree and 10 (17.5%) had a bachelor or higher degree. Participants had 4.1± 1.6 years of diabetes history (between 3 and 5 years) and they were using one or two daily doses of metformin (500 mg) plus a maximum one dose of glibenclamide (5 mg). None of the participants were smokers nor performed habitual exercise.

Baseline Measurements and Dietary Intake

There was no significant difference in baseline measures between the study groups except for muscle mass that was less in CE group when compared with the other three intervention groups (p < 0.05). The results of the analysis of food intake are shown in Table 1. The comparison of reported food intakes before and after intervention did not show any significant change (P > 0.05). This was expected as participants were instructed not to change their dietary habits and food intake.

Table 1.

Dietary intake at baseline and end of the interventions in the study groups.

Marker Control AE RE CE*
Pre (Mean ± SD) Post (Mean ± SD) p-valuea Pre (Mean ± SD) Post (Mean ± SD) p-valuea Pre (Mean ± SD) Post (Mean ± SD) p-valuea Pre (Mean ± SD) Post (Mean ± SD) p-valuea
Energy (kcal) 2,195 ± 138 2,217 ± 98 0.421 2,129 ± 199 2,321 ± 208 0.347 2,108 ± 172 2,142± 190 0.142 2,202 ± 182 2,281± 139 0.492
Protein (g) 81.70 ± 11.9 84.31 ± 9.4 0.461 80.91 ± 16.8 79.67 ± 14.2 0.513 74.12 ± 8.2 78.19 ± 8.6 0.232 86.86 ± 10.3 85.62 ± 12.4 0.500
Total fat (g) 66.35 ± 8.6 66.37 ± 9.0 0.512 65.42 ± 6.9 63.47 ± 9.8 0.280 68.83 ± 5.9 65.23 ± 5.1 0.114 69.43 ± 10.7 67.77 ± 7.9 0.263
Saturated fat (g) 14.2 ± 3.3 13.3 ± 5.3 0.413 18.86 ± 7.0 18.31 ± 8.1 0.149 16.22 ± 4.5 16.03 ± 4.9 0.502 16.1 ± 6.8 15.8 ± 5.5 0.788
Monounsaturated fat (g) 28.17 ± 6.4 28.43 ± 6.6 0.098 22.77 ± 7.6 24.19 ± 9.7 0.381 27.00 ± 12.2 26.98 ± 12.1 0.329 28.26 ± 12.7 27.06 ± 8.9 0.470
Polyunsaturated fat (g) 23.98 ± 6.8 24.64 ± 8.0 0.112 23.79 ± 8.9 20.97 ± 7.0 0.274 25.61 ± 9.0 22.22 ± 7.8 0.081 25.07 ± 7.4 24.91 ± 8.8 0.816
Carbohydrate (g) 339.91 ± 33.8 342.48 ± 43.4 0.308 339.19 ± 60.2 343.12 ± 41.20 0.202 321.42 ± 51.3 331.06 ± 46.0 0.068 300.85 ± 59.0 328.66 ± 53.6 0.147
Dietary fiber (g) 19.1 ± 6.3 19.4 ± 5.0 0.149 16.3 ± 2.9 17.10 0.371 15.8 ± 7.6 16.1 ± 6.3 0.215 18.0 ± 4.0 17.2 ± 3.3 0.322
Open in a new tab
a

p-value from the paired sample t-test comparing pre and post intervention dietary intake in each group.

*

This group performed both AE and RE simultaneously in one session.

Anthropometric and Body Composition

The summary of pre and post measurements and the results of the comparison between groups are presented in Table 2. Accordingly, we observed no significant changes in the control group, whereas, both AE and CG experienced significant reductions in body weight and BMI (p < 0.05). In addition, all of the three training groups had significantly lower body fat percentage and higher muscle mass after 12 weeks of intervention (p < 0.05). Regarding WHR, none of the study groups exhibited significant changes. Analysis of variance of the post-intervention measures indicates that only CE group had a lower muscle mass at the end of intervention when compared to the control group (p < 0.05). However, based on the results of ANCOVA using pre-test values as a covariate, body weight, BMI, body fat percent, and muscle mass in the CE group were significantly different from the control group. In addition, compared to the control group, both AE and RE groups had significantly lower body fat and higher muscle mass, respectively. According to the results, the CE group achieved significantly better anthropometric indices and lipid profile when compared to the control group (Figure 3).

Table 2.

Laboratory values, anthropometric measures in the groups at baseline and after 8 weeks of the interventions.

Marker Control (n = 14) AE (n = 14) RE (n = 14) CE (n = 15) P-valueb P-valuec P-valued
Pre (Mean ± SD) Post (Mean ± SD) P-valuea Pre (Mean ± SD) Post (Mean ± SD) P-valuea Pre (Mean ± SD) Post (Mean ± SD) P-valuea Pre (Mean ± SD) Post (Mean ± SD) P-valuea
Weight (Kg) 72.50 ± 10.67 73.10 ± 10.78 0.098 74.21 ± 6.88 73.17 ± 8.10 0.020 73.71 ± 9.10 72.97 ± 8.79 0.012 72.86 ± 8.74 74.21 ± 9.03* 0.017 0.955 0.873 0.004
BMI (kg/cm2) 29.09 ± 4.61 29.59 ± 4.81 0.099 29.25 ± 4.03 28.554.69 0.019 28.97 ± 2.95 28.59 ± 2.98 0.003 30.25 ± 3.34 28.42 ± 3.2* 0.016 0.789 0.857 0.002
WHR 0.88 ± 0.05 0.89 ± 0.05 0.208 0.88 ± 0.05 0.84 ± 0.09 0.083 0.88 ± 0.05 0.82 ± 0.09 0.073 0.87 ± 0.03 0.84 ± 0.09 0.077 0.950 0.233 0.175
Body fat (%) 33.75 ± 2.61 34.47 ± 2.80 0.323 34.88 ± 3.23 33.66 ± 3.42* 0.007 34.05 ± 3.62 33.10 ± 4.02 0.007 33.84 ± 3.50 32.12 ± 3.34* <0.001 0.787 0.310 0.003
Muscle mass (Kg) 39.54 ± 2.99 39.46 ± 2.46 0.704 39.82 ± 3.68 40.82 ± 3.30 0.017 39.61 ± 2.83 41.02 ± 2.89* <0.001 35.73 ± 6.66 36.99 ± 6.44* 0.001 0.040 0.042 0.002
SBP (mmHg) 133.08 ± 11.12 135.12 + 11.09 0.893 136.40 ± 15.21 131.22 + 10.30 0.214 131.17 ± 9.68 131.78 + 13.59 0.781 131.68 + 11.47 127.65 + 10.05 0.141 0.234 0.553 0.294
DBP (mmHg) 87.31 ± 9.14 88.06 + 7.5 0.452 91.02 ± 10.11 88.50 + 6.48 0.191 93.55 ± 8.99 90.04 + 10.10 0.243 89.21 + 10.19 86.87 + 8.92 0.172 0.411 0.298 0.412
FPG (mg/dL) 163.35 ± 21.81 164.35 ± 23.57 0.459 157.92 ± 31.37 153.15 ± 31.59* 0.003 158.92 ± 31.03 155.71 ± 28.99 0.037 162.15 ± 27.09 155.58 ± 27.21* <0.001 0.949 0.747 0.001
Insulin (μIU/mL) 10.34 ± 1.55 10.46 ± 1.70 0.514 10.62 ± 1.03 10.03 ± 0.91 0.004 10.66 ± 1.50 9.91 ± 1.56* 0.001 10.60 ± 1.35 9.05 ± 1.27*Δ# <0.001 0.930 0.059 <0.001
HOMA-IR 4.18 ± 0.85 4.20 ± 0.99 0.779 4.11 ± 0.74 3.69 ± 0.77* <0.001 4.13 ± 0.67 3.72 ± 0.68* 0.012 4.24 ± 0.95 3.48 ± 0.83* <0.001 0.977 0.137 <0.001
TG (mg/dL) 175.63 ± 27.01 177.13 ± 29.05 0.311 193.21 ± 50.12 190.42 ± 50.37 0.017 209.28 ± 54.95 202.64 ± 49.81 0.066 199.92 ± 34.17 191.76 ± 35.04* <0.001 0.216 0.464 0.016
LDL (mg/dL) 118.75 ± 32.25 120.59 ± 33.13 0.116 93.64 ± 16.86 91.57 ± 16.35 0.034 97.14 ± 34.37 94.71 ± 34.95 0.003 109.69 ± 35.94 104.38 ± 38.04* 0.003 0.130 0.083 0.001
HDL (mg/dL) 50.92 ± 11.71 52.50 ± 13.24 0.187 52.35 ± 10.42 56.92 ± 10.11 0.041 54.28 ± 12.28 56.64 ± 12.41 0.117 49.61 ± 8.93 53.69 ± 9.14 <0.001 0.693 0.665 0.415
Cholesterol (mg/dL) 184.85 ± 25.42 186.42 ± 27.02 0.303 189.85 ± 34.77 184.57 ± 34.52* <0.001 197.28 ± 15.96 193.50 ± 16.44 0.030 166.92 ± 37.76 161.84 ± 37.56* 0.003 0.053 0.037 0.002
Irisin-1 (ng/mL) 9.14 ± 1.27 9.07 ± 1.41 0.687 8.81 ± 0.99 9.41 ± 1.08* <0.001 9.42 ± 0.75 9.97 ± 1.12 <0.001 8.64 ± 0.87 9.47 ± 1.19* <0.001 0.167 0.281 0.003
Nesfatin-1 8.71 ± 1.39 8.88 ± 1.37 0.146 8.82 ± 1.33 9.64 ± 1.13* 0.002 9.34 ± 1.63 10.42 ± 1.69* 0.007 9.57 ± 1.52 10.58 ± 1.33* <0.001 0.350 0.007 0.001
Open in a new tab
a

Paired sample t-test,

b

One-way ANOVA between pre-test measurements,

c

One-way ANOVA between post-test measurements,

d

Analysis of covariance of post-test measurements with pre-test measurements as covariates. BMI, Body Mass Index; WHR, Waist to Hip Ratio; SBP, systolic Blood Pressure; DBP, Diastolic Blood Pressure; FPG, Fasting Plasma Glucose; HOMIIR, Homeostatic Model Assessment for Insulin Resistance; HDL, High-Density Lipoprotein; LDL, Low-Density Lipoprotein; TG, Triglyceride.

*

Significant difference vs. control group.

Δ

Significant difference vs. aerobic group.

#

Significant difference vs. resistance group.

Figure 3.

Figure 3

Open in a new tab

Comparison of changes in anthropometric and lipid profile between the groups. *Significant difference in comparison with the control group (p < 0.05). AE, aerobic exercise; RE, resistant exercise; CE, combined exercise.

Glycemic and Lipid Indices

As expected, exercise training significantly reduced the FPG, fasting insulin and HOMA-IR in all intervention groups. However, the comparison of post-intervention measures between the study groups did not show any significant difference. Conversely, analysis of covariance demonstrated a significant reduction in FPG in CE and AE groups in comparison with the control group. When compared with the control group, the fasting serum insulin reduced significantly in the CE and RE groups. However, the reduction in CE (14%) group was even greater than what was observed in the AE and RE groups (5 and 7%, respectively). In addition, disregarding the exercise protocols, all the training groups exhibited significant reductions in insulin resistance in comparison with the control group. Both aerobic and combined exercises training programs improved lipid profile (TG, LDL, HDL, and total cholesterol) after 12 weeks of intervention. In the case of resistant exercise, the improvement was limited to LDL and total cholesterol. In comparison with the control group, the CE group experienced a higher reduction in TG, LDL, and total cholesterol. Nevertheless, a similar result was observed only in the reduction of total cholesterol in the AE group (Table 2).

Irisin-1 and Nesfatin-1

The serum concentration of irisin-1 and nesfatin-1 raised significantly after exercise training in three intervention groups except for irisin-1 in the RE group. The effectiveness of exercise on the increase of serum irisin-1 and nesfatin-1 remained significant after they were compared with the control group. As shown in Figure 4, the CE group had significantly better improvements in glycemic indices, serum irisin-1 and nesfatin-1 when compared with the control group.

Figure 4.

Figure 4

Open in a new tab

Comparison of changes in glycemic indices Irisin-1 and nesfatin-1 between the groups. *Significant difference in comparison with the control group (p < 0.05). AE, aerobic exercise; RE, resistant exercise; CE, combined exercise.

Exploring the correlation between the observed changes in irisin-1, nesfatin-1 and anthropometric and metabolic indices among all the participants (Table 3) showed that irisin-1 was negatively and significantly correlated with body weight, BMI, body fat percent, fasting insulin, and HOMA-IR. Whereas, the increase in nesfatin-1 was significantly correlated with the reduction in body fat percent and LDL-cholesterol.

Table 3.

Correlation between irisin-1/nesfatin-1 and metabolic and anthropometric parameters.

Markers Weight BMI WHR Body fat Muscle FPG Insulin HOMI-IR TG LDL HDL Cholesterol Irisin-1 Nesfatin-1
Irisin−1 −0.271* −0.278* −0.141 −0.377** 0.200 −0.256 −0.264* −0.337* −0.067 −0.157 −0.094 −0.245 1 0.242
Nesfatin−1 −0.169 −0.185 −0.118 −0.0265* 0.020 −0.155 −0.178 −0.120 −0.037 −0.328* −0.046 −0.069 0.242 1
Open in a new tab

BMI, Body Mass Index; WHR, Waist to Hip Ratio; FPG, Fasting Plasma Glucose; HOMIIR, Homeostatic Model Assessment for Insulin Resistance; HDL, High-Density Lipoprotein; LDL, Low-Density Lipoprotein; TG, Triglyceride.

*

Significant correlation at the 0.05 level.

**

Significant correlation at the 0.01 level.

Discussion

This study aimed to compare the effects of 12 weeks of aerobic, resistance, and the combination of aerobic and resistance exercises on the serum levels of nesfatin-1 and irisin-1, anthropometric and glycemic indices, and lipid profiles of women with metabolic syndrome. The main finding of this randomized controlled trial was that the exercises in all intervention groups improved the serum concentration of irisin-1 and nesfatin-1. Except for serum irisin-1 in the RE group the effect of the exercise programs on the improvement in serum irisin-1 and nesfatin-1 was significant (when compared with the control group). We also found that serum irisin-1 was negatively and significantly correlated with body weight, BMI, body fat percent, fasting insulin, and HOMA-IR. Whereas, the increase of nesfatin-1 was correlated with a reduction of body fat percent and LDL-cholesterol. Accordingly, exercise training in all intervention groups reduced post-test FPG, fasting insulin and HOMA-IR. Also, a significant reduction in body weight and BMI was observed in the AE and CG groups.

The underlying mechanism of the exercise-induced nesfatin-1 response is not well-documented. Nesfatin-1 is synthesized in the central and peripheral nervous system as well as in the adipose tissue and is subsequently released into the blood circulation (Mogharnasi et al., 2019b). Nesfatin-1 exerts various actions at the level of nervous and digestive systems and plays a role in stress response and thermogenesis. It is believed that nesfatin-1 not only overwhelms appetite and therefore food intake but also it may affect energy expenditure and glucose homeostasis (Huang et al., 2008). By controlling the dietary habits of individuals, we found that 12-weeks exercise training increases nesfatin-1 among all three intervention groups. It has been hypothesized that nesfatin-1 modifies glucose homeostasis by mechanisms that increase glucose uptake and insulin sensitivity (Li et al., 2013). A previous study demonstrated that serum nesfatin-1 and insulin sensitivity in obese men were increased after upper-body resistance exercise was conducted (Mogharnasi et al., 2019b). Altogether, our results are consistent with the previous studies that showed an upsurge in nesfatin-1 and insulin sensitivity following high-intensity training (Ahmadizad et al., 2015; Ozcelik et al., 2018; Mogharnasi et al., 2019b). Moreover, another study reported that the reduction in nesfatin-1 induced by a high-fat diet is suppressed by the running wheel in mice (Chaolu et al., 2011). Nesfatin-1 reduces blood glucose by activating AMP-activated protein kinase, up-regulating the phosphorylation of protein kinase B in the pancreas, and by increasing the glucose transporter-4 membrane translocation in skeletal muscle and adipose tissue that in turn improves insulin sensitivity (Le et al., 2016). In line with our findings, a study suggested that nesfatin-1, weight, and fat percentage are likely to be improved significantly in response to a long-term exercise (Yazici, 2015). On the other hand, increased levels of the adipocytokine induced change by exercise can act as stimuli in reducing visceral and subcutaneous fat. In accordance with our results, a negative correlation has been reported between nesfatin-1 and variables such as body fat percentage by a few previous studies (Tsuchiya et al., 2010; Mogharnasi et al., 2019b). In addition, it has been reported that 8 weeks of moderate-intensity aerobic exercise diminished BMI and insulin and raised serum levels of nesfatin-1 in obese women (Nabil and El Sayyad, 2015). As noted in the literature, nesfatin-1 is highly sensitive to long-term training and significant loss of weight and fat percentage (Nabil and El Sayyad, 2015; Mogharnasi et al., 2019a).

Secretion of nesfatin-1 may contribute to the treatment of obesity and diabetes because of its anorexigenic and antihyperglycemic effects and even it may have effects on depression and anxiety (Schalla and Stengel, 2018). These pieces of evidence suggest that long term exercise training might be an effective way to increase nesfatin-1. Because of these beneficial effects, nesfatin-1 may be a potential regulatory agent that exerts therapeutic effects of exercise training on some chronic diseases including obesity, type 2 diabetes, and metabolic syndrome (Schalla and Stengel, 2018; Öztürk Özkan G., 2020).

Previous studies have examined the effects of different exercise programs on serum irisin-1. Nevertheless, their results are not convincedly consistent to warrant a firm conclusion. We previously found that an 8-week exercise training program resulted in a non-significant change in circulating irisin-1 (Dianatinasab et al., 2020). Interestingly, after 12 weeks of intervention, we found that long term exercise program may have a direct effect on serum levels of irisin-1. In line with the findings of the current study, Huh et al. (2015) suggested that regardless of the participants' age, fitness level, or health status, different exercise regimens, including high-intensity swimming, treadmill, and resistance exercise, increase the level of circulating irisin-1. Similarly, Daskalopoulou et al. (2014) reported that three different exercise protocols significantly increased serum irisin-1 serum level, especially after the maximal exercise workload.

Comparing the results of previous studies with our findings, Kim et al. (2016) found that circulating irisin-1 level was increased by 8 weeks of resistance training in overweight/obese adults. They suggested that resistance training is beneficial to overweight/obese individuals. In line with the findings of the present study, the authors reported a significant change in body composition concomitant with an increase in serum irisin-1 level.

There are also reported that neither of aerobic, resistance, or combined exercises did increase serum irisin-1 levels (Dianatinasab et al., 2020). It should be noted that the reported non-significant change in serum irisin-1 may be due to the difference in the training regimens (60 min, 5 times/week vs. 60 min, 3 times/week).

Norheim et al. reported that the serum level of irisin-1 was increased right after 45 min of ergometer cycling and dropped 2 h after the exercise. Since the production of irisin-1 depends on PGC-1α activity and FNDC5 transcription, during an acute exercise, the sharp increase in serum irisin-1 could be due to FNDC5 mRNA translation rather than FNDC5 transcription (Norheim et al., 2014). As Norheim et al. declared, PGC-1α transcription and FNDC5 mRNA expression increased significantly after 12 weeks of systematic exercise, but these changes did not translate to a higher concentration of serum irisin-1. These discrepant results could be due to differences in study designs as Norheim et al. prescribed training exercise for both control and intervention groups and the blood samples were collected immediately and 2 h after training sessions.

In addition to acute or chronic exercise interventions, patients' anthropometric and health status may also affect the results. In our study, the female participants were overweight and obese and were diagnosed with metabolic syndrome. Similarly, the participants in a study by Norheim et al. were obese and prediabetic volunteers, but Pekkala et al. (2013) focused on healthy men, and their findings did not confirm the positive effects of AE, RE, and CE on irisin-1. Timmons et al. studied the effects of endurance and resistance exercise for 6 weeks on two different groups, including healthy individuals and those with type II diabetes. The results showed greater expression of FNDC5 in the intervention group compared with that of the control group (Timmons et al., 2012). Although Osella et al. (2018) examined the effects of different diets on the serum irisin-1 concentration and found that vegetable proteins and saturated fatty acids were positively associated with serum irisin-1. The authors did not examine the effects of exercise on serum irisin-1 concentration. To address the above issue, our study used a dietary regimen based on the pre-intervention dietary intake to adjust the effect of dietary components on serum irisin-1.

As expected, the exercise interventions induced a positive change in glycemic indices, and the change was bigger in the CE group. Our results were similar to those of a previous study that evaluated the efficacy of different exercise regimens on serum omentin-1 in diabetic women (AminiLari et al., 2017). The Pearson correlation showed that changes in the HOMA-IR, body weight and body fat percentage were correlated negatively with serum irisin-1 in all participants. Positive relationships between serum irisin-1 and metabolic disorders, such as obesity, diabetes, and cardiovascular diseases, are reported by previous studies (Sesti et al., 2014; Shoukry et al., 2016). Stengel et al. (2013) showed that obese patients had a higher level of circulating irisin-1 than normal subjects. In addition, serum irisin-1 was negatively correlated with fat mass and insulin resistance. Our study showed that the reduction in insulin resistance or body fat percentage is associated with higher serum irisin-1. Crujeiras et al. (2014) reported that the circulating irisin-1 was increased proportionally to the weight regain after patients underwent a calorie-restricted weight reduction diet.

There are two hypotheses to explain the underlying mechanisms behind the association of serum irisin-1 and weight gain. In the first hypothesis, an increase in the serum irisin-1 is an adaptive response to weight gain and an increase in body fat. Accordingly, the conversion of white fat tissue to brown adipose tissue can increase thermogenesis and energy consumption, and eventually, lead to weight loss through myokine irisin-1 (Bostrom et al., 2012). Irisin-1 stimulates the expression and activity of uncoupling protein1 (UCP1) and causes the browning of the white adipose tissue. Therefore, it increases thermogenesis and total energy expenditure that in turn, can reduce obesity (O'Neill and O'Driscoll, 2015; Zhang et al., 2016). This hypothesis was supported by the results of an animal study, in which irisin-1 improved hyperinsulinemia and glucose tolerance in mice with a high-fat diet (Zhang et al., 2014). In the second hypothesis, an increase in serum irisin-1 in adiposity may induce irisin-1 resistance. Irisin-1 is supposed to improve UCP1 production and promote the browning of white adipose tissues. However, it is contradictory that normal weight or anorexic patients have lower levels of circulating irisin-1 than obese individuals. While adipose tissue itself secretes irisin-1, an increase in the body fat and irisin-1 secretion does not lead to expected beneficial effects and leptin resistance (Sahin-Efe et al., 2018).

In the present study, a negative and significant correlation between change in irisin-1 concentration and HOMA-IR was observed. Similar to body fat and BMI, cross-sectional studies have reported a positive association between serum irisin-1 and insulin resistance (Hee Park et al., 2013; Sesti et al., 2014). At first sight, these results contravene our results, however, when considering the correlation between change in irisin-1 and glycemic status, there are several resembling studies. Yang et al. have shown that administration of irisin-1 to murine myocytes under an insulin-resistant state recovers insulin action (Yang et al., 2015). Reinehr et al. also have reported that in children who underwent lifestyle changes, the change in serum irisin-1 was reversely associated with fasting glucose and 2-h glucose of oral glucose tolerance test (Reinehr et al., 2015). Finally, it should be mentioned that there are debates on the accuracy of commercial ELISA kits to detect irisin-1. The developed antibodies for irisin-1 in these kits may bind to other proteins with a similar pattern too that could compromise the precision of the measurements. On the other hand, alternate methods such as mass spectrometry are more specificity but add more steps to sample preparation which adds uncontrolled deviation to the measurements (Albrecht et al., 2020).

Besides the evidence of improvement in the lipid profile in the training groups, no significant correlation was observed between these changes and serum irisin-1 and nesfatin-1, with one exception for a negative correlation between nesfatin-1 and LDL-cholesterol. While previous studies have shown a positive correlation between lipid profile and irisin-1 concentration in adolescents and adults (Shoukry et al., 2016; Jang et al., 2017). Contrary to recent studies that used a cross-sectional design, in the present study we conducted a randomized control trial to examine the correlations between the changes in irisin-1/nesfatin-1 concentration and serum lipids. To the best of our knowledge, no other RCTs have investigated the relationship.

Study Strengths and Limitations

As a limitation, the inclusion of the expression of the FND5 gene in skeletal muscle and fat mass could reveal the source of circulating irisin-1 in the body. Also, we recruited women from a specific age range that may influence the generalizability of our results to the whole population. Accordingly, our results should be interpreted with caution when other age groups are considered. On the other hand, the process of evaluating the dietary intake before and after the intervention and using a dietary regimen based on the pre-intervention intake improved the quality of data collection and can be considered a strength of this study. So, a strength of the study is that it was diet-controlled. Besides, we asked (and monitored) the participants not to change their dietary habits during the study.

Conclusions

We found that 12 weeks of training resulted in an increase in irisin-1 in the AE and CE groups and an increase in nesfatin-1 in all the intervention groups. Moreover, all the trained groups exhibited a positive alteration in anthropometric and glycemic indices and lipid profile in comparison with the control group. As nesfatin-1 and irisin-1 play many vital roles in glucose homeostasis as a regulator of glucose levels and energy expenditure, taking advantage of our results, and considering these beneficial effects, exercise training may be a safe and accessible strategy for most patients with metabolic syndrome to improve the effect of irisin-1 and nesfatin-1 on metabolic factors. Besides, the inconsistent findings on the effect of exercise in serum irisin-1 levels highlight the need for larger-scale RCTs on healthy and non-healthy participants.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics Statement

The studies involving human participants were reviewed and approved by Ethics Committee of Shiraz University of Medical Sciences. The patients/participants provided their written informed consent to participate in this study.

Author Contributions

SA, ES, and AD co-designed the study and surveyed the materials. MP and RM were involved in data collection. SA, MF, AD, and ZB-H were responsible for conducting the statistical analyses, interpreting the data, and drafting the manuscript. SA and MF revised the manuscript critically for important content. All authors approved the final manuscript to be submitted and published.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors would like to thank the participation of the women in this study.

Glossary

Abbreviations

MetS

Metabolic Syndrome

AE

Aerobic Exercise

RE

Resistant Exercise

CE

Combined Exercise

HOMA-IR

Homeostatic Model Assessment for Insulin Resistance

FPG

Fasting plasma glucose

SD

Standard Deviation

BMI

Body Mass Index

WHR

Waist-to-Hip Ratio

HDL

High-Density Lipoprotein

LDL

Low-Density Lipoprotein

TG

Triglyceride

UCP1

Uncoupling Protein-1

FNDC5

Fibronectin Type III Domain-Containing Protein 5.

Footnotes

Funding. This research was supported under a research grant (Grant No: 17589) from Shiraz University of Medical Sciences, Iran. The study funder had no role in study design, data collection, writing of the manuscript, and submission.

References

  1. Ahmadizad S., Avansar A. S., Ebrahim K., Avandi M., Ghasemikaram M. (2015). The effects of short-term high-intensity interval training vs. moderate-intensity continuous training on plasma levels of nesfatin-1 and inflammatory markers. Horm. Mol. Biol. Clin. Investig. 21, 165–173. 10.1515/hmbci-2014-0038 [DOI] [PubMed] [Google Scholar]
  2. Albrecht E., Schering L., Buck F., Vlach K., Schober H.-C., Drevon C. A., et al. (2020). Irisin: Still chasing shadows. Mol. Metab. 34, 124–135. 10.1016/j.molmet.2020.01.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Algul S., Ozdenk C., Ozcelik O. (2017). Variations in leptin, nesfatin-1 and irisin levels induced by aerobic exercise in young trained and untrained male subjects. Biol. Sport 34, 339–344. 10.5114/biolsport.2017.69821 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Amanat S., Ghahri S., Dianatinasab A., Fararouei M., Dianatinasab M. (2020). Exercise and type 2 diabetes. Adv. Exp. Med. Biol. 1228, 91–105. 10.1007/978-981-15-1792-1_6 [DOI] [PubMed] [Google Scholar]
  5. AminiLari Z., Fararouei M., Amanat S., Sinaei E., Dianatinasab S., AminiLari M., et al. (2017). The effect of 12 weeks aerobic, resistance, and combined exercises on omentin-1 levels and insulin resistance among type 2 diabetic middle-aged women. Diabetes Metab. J. 41, 205–212. 10.4093/dmj.2017.41.3.205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bajer B., Vlcek M., Galusova A., Imrich R., Penesova A. (2015). Exercise associated hormonal signals as powerful determinants of an effective fat mass loss. Endocr. Regul. 49, 151–163. 10.4149/endo_2015_03_151 [DOI] [PubMed] [Google Scholar]
  7. Bostrom P., Wu J., Jedrychowski M. P., Korde A., Ye L., Lo J. C., et al. (2012). A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463–468. 10.1038/nature10777 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brzycki M. (1993). Strength testing—predicting a one-rep max from reps-to-fatigue. J. Phys. Educ. Recreat. Dance 64, 88–90. 10.1080/07303084.1993.10606684 [DOI] [Google Scholar]
  9. Chaolu H., Asakawa A., Ushikai M., Li Y.-X., Cheng K.-C., Li J.-B., et al. (2011). Effect of exercise and high-fat diet on plasma adiponectin and nesfatin levels in mice. Exp. Ther. Med. 2, 369–373. 10.3892/etm.2011.199 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Choi Y. K., Kim M. K., Bae K. H., Seo H. A., Jeong J. Y., Lee W. K., et al. (2013). Serum irisin levels in new-onset type 2 diabetes. Diabetes Res. Clin. Pract. 100, 96–101. 10.1016/j.diabres.2013.01.007 [DOI] [PubMed] [Google Scholar]
  11. Crujeiras A. B., Zulet M. A., Lopez-Legarrea P., de la Iglesia R., Pardo M., Carreira M. C., et al. (2014). Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metab. Clin. Exp. 63, 520–531. 10.1016/j.metabol.2013.12.007 [DOI] [PubMed] [Google Scholar]
  12. Daskalopoulou S. S., Cooke A. B., Gomez Y. H., Mutter A. F., Filippaios A., Mesfum E. T., et al. (2014). Plasma irisin levels progressively increase in response to increasing exercise workloads in young, healthy, active subjects. Eur. J. Endocrinol. 171, 343–352. 10.1530/EJE-14-0204 [DOI] [PubMed] [Google Scholar]
  13. Dianatinasab A., Koroni R., Bahramian M., Bagheri-Hosseinabadi Z., Vaismoradi M., Fararouei M., et al. (2020). The effects of aerobic, resistance, and combined exercises on the plasma irisin levels, HOMA-IR, and lipid profiles in women with metabolic syndrome: a randomized controlled trial. J. Exerc. Sci. Fitness 18, 168–176. 10.1016/j.jesf.2020.06.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Expert Panel on Detection E. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486 10.1001/jama.285.19.2486 [DOI] [PubMed] [Google Scholar]
  15. Fox J., Rioux B. V., Goulet E. D. B., Johanssen N. M., Swift D. L., Bouchard D. R., et al. (2018). Effect of an acute exercise bout on immediate post-exercise irisin concentration in adults: a meta-analysis. Scand. J. Med. Sci. Sports 28, 16–28. 10.1111/sms.12904 [DOI] [PubMed] [Google Scholar]
  16. Ghanbari-Niaki A., Kraemer R. R., Soltani R. (2010). Plasma nesfatin-1 and glucoregulatory hormone responses to two different anaerobic exercise sessions. Eur. J. Appl. Physiol. 110, 863–868. 10.1007/s00421-010-1531-6 [DOI] [PubMed] [Google Scholar]
  17. Haff G. G., Triplett N. T. (2015). Essentials of Strength Training and Conditioning. 4th Edn. Human Kinetics. pp. 752. [Google Scholar]
  18. Hawley J. A., Holloszy J. O. (2009). Exercise: it's the real thing! Nutr. Rev. 67, 172–178. 10.1111/j.1753-4887.2009.00185.x [DOI] [PubMed] [Google Scholar]
  19. Hee Park K., Zaichenko L., Brinkoetter M., Thakkar B., Sahin-Efe A., Joung K. E., et al. (2013). Circulating irisin in relation to insulin resistance and the metabolic syndrome. J. Clin. Endocrinol. Metab. 98, 4899–4907. 10.1210/jc.2013-2373 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Huang C.-C., Liu C.-W., Weng M.-C., Chen T.-W., Huang M.-H. (2008). Association of C-reactive protein and insulin resistance in patients with chronic spinal cord injury. J. Rehabil. Med. 40, 819–822. 10.2340/16501977-0264 [DOI] [PubMed] [Google Scholar]
  21. Huh J. Y., Panagiotou G., Mougios V., Brinkoetter M., Vamvini M. T., Schneider B. E., et al. (2012). FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metab. Clin. Exp. 61, 1725–1738. 10.1016/j.metabol.2012.09.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Huh J. Y., Siopi A., Mougios V., Park K. H., Mantzoros C. S. (2015). Irisin in response to exercise in humans with and without metabolic syndrome. J. Clin. Endocrinol. Metab. 100, E453–E457. 10.1210/jc.2014-2416 [DOI] [PubMed] [Google Scholar]
  23. Jang H. B., Kim H. J., Kang J. H., Park S. I., Park K. H., Lee H. J. (2017). Association of circulating irisin levels with metabolic and metabolite profiles of Korean adolescents. Metab. Clin. Exp. 73, 100–108. 10.1016/j.metabol.2017.05.007 [DOI] [PubMed] [Google Scholar]
  24. Kaur J. (2014). A comprehensive review on metabolic syndrome. Cardiol. Res. Pract. 2014:943162. 10.1155/2014/943162 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  25. Kim H.-J., Lee H.-J., So B., Son J. S., Yoon D., Song W. (2016). Effect of aerobic training and resistance training on circulating irisin level and their association with change of body composition in overweight/obese adults: a pilot study. Physiol. Res. 65, 271–279. 10.33549/physiolres.932997 [DOI] [PubMed] [Google Scholar]
  26. Le S, Mao L., Lu D., Yang Y., Tan X., Wiklund P., et al. (2016). Effect of aerobic exercise on insulin resistance and central adiposity disappeared after the discontinuation of intervention in overweight women. J. Sport Health Sci. 5, 166–170. 10.1016/j.jshs.2016.04.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Li Z., Gao L., Tang H., Yin Y., Xiang X., Li Y., et al. (2013). Peripheral effects of nesfatin-1 on glucose homeostasis. PLoS ONE 8:e71513. 10.1371/journal.pone.0071513 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Luo L., Liu M. (2016). Adipose tissue in control of metabolism. J. Endocrinol. 231, R77–r99. 10.1530/JOE-16-0211 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Moghaddam M. B., Aghdam F. B., Jafarabadi M. A., Allahverdipour H., Nikookheslat S. D., Safarpour S. (2012). The Iranian version of international physical activity questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl. Sci. J 18, 1073–1080. Available online at: https://www.idosi.org/wasj/wasj18(8)12/7.pdf [Google Scholar]
  30. Mogharnasi M., TaheriChadorneshin H., Abbasi-Deloei N. (2019a). Effect of exercise training type on plasma levels of vaspin, nesfatin-1, and high-sensitivity C-reactive protein in overweight and obese women. Obes. Med. 13, 34–38. 10.1016/j.obmed.2018.12.006 [DOI] [Google Scholar]
  31. Mogharnasi M., TaheriChadorneshin H., Papoli-Baravati S. A., Teymuri A. (2019b). Effects of upper-body resistance exercise training on serum nesfatin-1 level, insulin resistance, and body composition in obese paraplegic men. Disabil. Health J. 12, 29–34. 10.1016/j.dhjo.2018.07.003 [DOI] [PubMed] [Google Scholar]
  32. Nabil N., El Sayyad M. (2015). Moderate exercise training has anorexogenic effect associated with improved oxidative stress in obese women. Int. J. Nutr. Metab. 7, 52–61. 10.5897/IJNAM2015.0180 [DOI] [Google Scholar]
  33. Norheim F., Langleite T. M., Hjorth M., Holen T., Kielland A., Stadheim H. K., et al. (2014). The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. FEBS J. 281, 739–749. 10.1111/febs.12619 [DOI] [PubMed] [Google Scholar]
  34. Oh I. S., Shimizu H., Satoh T., Okada S., Adachi S., Inoue K., et al. (2006). Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443, 709–712. 10.1038/nature05162 [DOI] [PubMed] [Google Scholar]
  35. O'Neill S., O'Driscoll L. (2015). Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes. Rev. 16, 1–12. 10.1111/obr.12229 [DOI] [PubMed] [Google Scholar]
  36. Osella A. R., Colaianni G., Correale M., Pesole P. L., Bruno I., Buongiorno C., et al. (2018). Irisin serum levels in metabolic syndrome patients treated with three different diets: a post-hoc analysis from a randomized controlled clinical trial. Nutrients 10:844. 10.3390/nu10070844 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ozcelik O., Algul S., Yilmaz B. (2018). Nesfatin-1 and irisin levels in response to the soccer matches performed in morning, afternoon and at night in young trained male subjects. Cell. Mol. Biol. 64, 130–133. 10.14715/cmb/2018.64.10.21 [DOI] [PubMed] [Google Scholar]
  38. Öztürk Özkan G . (2020). Effects of nesfatin-1 on food intake and hyperglycemia. J. Am. Coll. Nutr. 39, 345–351. 10.1080/07315724.2019.1646678 [DOI] [PubMed] [Google Scholar]
  39. Pekkala S., Wiklund P. K., Hulmi J. J., Ahtiainen J. P., Horttanainen M., Pollanen E., et al. (2013). Are skeletal muscle FNDC5 gene expression and irisin release regulated by exercise and related to health? J. Physiol. 591, 5393–5400. 10.1113/jphysiol.2013.263707 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Polyzos S. A., Anastasilakis A. D., Efstathiadou Z. A., Makras P., Perakakis N., Kountouras J., et al. (2018). Irisin in metabolic diseases. Endocrine 59, 260–274. 10.1007/s12020-017-1476-1 [DOI] [PubMed] [Google Scholar]
  41. Reinehr T., Elfers C., Lass N., Roth C. L. (2015). Irisin and its relation to insulin resistance and puberty in obese children: a longitudinal analysis. J. Clin. Endocrinol. Metab. 100, 2123–2130. 10.1210/jc.2015-1208 [DOI] [PubMed] [Google Scholar]
  42. Sahin-Efe A., Upadhyay J., Ko B. J., Dincer F., Park K. H., Migdal A., et al. (2018). Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: a cross sectional and a prospective case-control study nested in the normative aging study. Metab. Clin. Exp. 79, 24–32. 10.1016/j.metabol.2017.10.011 [DOI] [PubMed] [Google Scholar]
  43. Schalla M. A., Stengel A. (2018). Current understanding of the role of nesfatin-1. J. Endocr. Soc. 2, 1188–1206. 10.1210/js.2018-00246 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sesti G., Andreozzi F., Fiorentino T. V., Mannino G. C., Sciacqua A., Marini M. A., et al. (2014). High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol. 51, 705–713. 10.1007/s00592-014-0576-0 [DOI] [PubMed] [Google Scholar]
  45. Shabani R., Izaddoust F. (2018). Effects of aerobic training, resistance training, or both on circulating irisin and myostatin in untrained women. Acta Gymnica 48, 47–55. 10.5507/ag.2018.007 [DOI] [Google Scholar]
  46. Shoukry A., Shalaby S. M., El-Arabi Bdeer S., Mahmoud A. A., Mousa M. M., Khalifa A. (2016). Circulating serum irisin levels in obesity and type 2 diabetes mellitus. IUBMB Life 68, 544–556. 10.1002/iub.1511 [DOI] [PubMed] [Google Scholar]
  47. Stengel A., Hofmann T., Goebel-Stengel M., Elbelt U., Kobelt P., Klapp B. F. (2013). Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 39:125–130. 10.1016/j.peptides.2012.11.014 [DOI] [PubMed] [Google Scholar]
  48. Tanaka H., Monahan K. D., Seals D. R. (2001). Age-predicted maximal heart rate revisited. J. Am. Coll. Cardiol. 37, 153–156. 10.1016/S0735-1097(00)01054-8 [DOI] [PubMed] [Google Scholar]
  49. Timmons J. A., Baar K., Davidsen P. K., Atherton P. J. (2012). Is irisin a human exercise gene? Nature 488, E9–E10, discussion E-1. 10.1038/nature11364 [DOI] [PubMed] [Google Scholar]
  50. Tsuchiya T., Shimizu H., Yamada M., Osaki A., Oh -I. S, Ariyama Y., et al. (2010). Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin. Endocrinol. 73, 484–490. 10.1111/j.1365-2265.2010.03835.x [DOI] [PubMed] [Google Scholar]
  51. Wang H., Zhao Y. T., Zhang S., Dubielecka P. M., Du J., Yano N., et al. (2017). Irisin plays a pivotal role to protect the heart against ischemia and reperfusion injury. J. Cell. Physiol. 232, 3775–3785. 10.1002/jcp.25857 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Wang Z., Chen K., Han Y., Zhu H., Zhou X., Tan T., et al. (2018). Irisin protects heart against ischemia-reperfusion injury through a SOD2-dependent mitochondria mechanism. J. Cardiovasc. Pharmacol. 72, 259–269. 10.1097/FJC.0000000000000608 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Whillier S. (2020). Exercise and insulin resistance. Adv. Exp. Med. Biol. 1228, 137–150. 10.1007/978-981-15-1792-1_9 [DOI] [PubMed] [Google Scholar]
  54. World Health Organization (1995). Physical Status: The Use of and Interpretation of Anthropometry. Geneva: WHO Expert Committee; Available online at: https://apps.who.int/iris/handle/10665/37003 [PubMed] [Google Scholar]
  55. Yang Z., Chen X., Chen Y., Zhao Q. (2015). Decreased irisin secretion contributes to muscle insulin resistance in high-fat diet mice. Int. J. Clin. Exp. Pathol. 8, 6490–6497. [PMC free article] [PubMed] [Google Scholar]
  56. Yazici A. G. (2015). Relationship and interaction between anaerobic sports branches and serum nesfatin-1. Turk. J. Phys. Med. Rehab. 61, 234–240. 10.5152/tftrd.2015.57124 [DOI] [Google Scholar]
  57. Zhang Y., Li R., Meng Y., Li S., Donelan W., Zhao Y., et al. (2014). Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 63, 514–525. 10.2337/db13-1106 [DOI] [PubMed] [Google Scholar]
  58. Zhang Y., Xie C., Wang H., Foss R. M., Clare M., George E. V., et al. (2016). Irisin exerts dual effects on browning and adipogenesis of human white adipocytes. Am. J. Physiol. Endocrinol. Metab. 311, E530–E541. 10.1152/ajpendo.00094.2016 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Articles from Frontiers in Physiology are provided here courtesy of Frontiers Media SA

RESOURCES